Efficacy and Safety of Almonertinib Versus Placebo as Adjuvant Therapy for Subjects With Resected Stage II-IIIB NSCLC Harboring EGFR-sensitive Mutations: A Randomized, Controlled, Double-blind, Phase 3 and Multicenter Clinical Study
Latest Information Update: 17 Jun 2022
At a glance
- Drugs Aumolertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 13 Jun 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 31 Dec 2020 New trial record